Cargando…
JBPOS0101 regulates amyloid beta, tau, and glial cells in an Alzheimer’s disease model
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease characterized by cognitive dysfunction and memory loss as the main symptoms. The deposition of amyloid beta (Aβ) and tau hyperphosphorylation are hallmarks of AD and are major therapeutic targets. However, the exact etiology ha...
Autores principales: | Jeong, Jihoon, Park, Hyung Joon, Mun, Bo-Ram, Jang, Ju Kyong, Choi, Yong Moon, Choi, Won-Seok |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426148/ https://www.ncbi.nlm.nih.gov/pubmed/32791516 http://dx.doi.org/10.1371/journal.pone.0237153 |
Ejemplares similares
-
Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum
por: Milà‐Alomà, Marta, et al.
Publicado: (2020) -
The Role of Amyloid-Beta and Tau in the Early Pathogenesis of Alzheimer’s Disease
por: Yin, Xiaomin, et al.
Publicado: (2021) -
Amyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease
por: Roda, Alejandro R., et al.
Publicado: (2022) -
Detection of Alzheimer's disease amyloid beta 1‐42, p‐tau, and t‐tau assays
por: van Harten, Argonde C., et al.
Publicado: (2021) -
Blood Beta-Amyloid and Tau in Down Syndrome: A Comparison with Alzheimer’s Disease
por: Lee, Ni-Chung, et al.
Publicado: (2017)